1. Home
  2. ODV vs MGTX Comparison

ODV vs MGTX Comparison

Compare ODV & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Osisko Development Corp.

ODV

Osisko Development Corp.

HOLD

Current Price

$2.35

Market Cap

807.5M

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$11.74

Market Cap

909.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ODV
MGTX
Founded
2005
2015
Country
Canada
United States
Employees
102
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
807.5M
909.1M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
ODV
MGTX
Price
$2.35
$11.74
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$24.57
AVG Volume (30 Days)
2.8M
762.2K
Earning Date
08-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.02
EPS
N/A
N/A
Revenue
N/A
$81,391,000.00
Revenue This Year
N/A
$141.38
Revenue Next Year
$2.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
144.57
52 Week Low
$2.06
$6.31
52 Week High
$4.80
$11.90

Technical Indicators

Market Signals
Indicator
ODV
MGTX
Relative Strength Index (RSI) 33.91 70.94
Support Level N/A $7.10
Resistance Level $3.50 $11.85
Average True Range (ATR) 0.14 0.61
MACD 0.00 0.26
Stochastic Oscillator 5.13 83.78

Price Performance

Historical Comparison
ODV
MGTX

About ODV Osisko Development Corp.

Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company projects include Cariboo Gold Project, Tintic Project, and Exploration.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: